- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03882281
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia (CML)
January 19, 2020 updated by: Ascentage Pharma Group Inc.
A Randomized, Open, Double-crossing Trial to Evaluate the Effect of Fasting or High-fat Meals on the Pharmacokinetics of Single Oral Administration of HQP1351 Tablets on an Empty Stomach or a High-fat Meal in Patients With Chronic Myeloid Leukemia
The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and fasting meals separately(Selection of high-fat meal spectrum:《The Food - Effect Bioavailability and Fed Bioequivalence Studies》high fat diet should be 800-1000 kcal heat.).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The drug being test in this study is HQP1351,the study will characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia(CML)in chronic phase(CP)after high-fat meal and fasting meal separately at a dose of 30mg,single-dose.
The study will enroll 12 subjects totally and be randomly divided into 2 groups(A group and B group).
Every group will have 6 subjects.
The experiment is divided into two periods,in period 1, subjects in the group A will be given HQP1351 30mg after fasting meal,and the group B will be given HQP1351 30mg after 30 minutes of high-fat meal.
Then after a seven-day of cleaning time the two groups of subjects took the drug interchangeably in the period 2.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Peking University People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or non-pregnant, non-lactating female patients age 18-55 years old.
- CML Patients in CP with Ph-positive or BCR/ABL-positive.
- Previously treated with and or developed resistance / intolerance to second generation tyrosine kinase inhibitors (TKIs) (dasatinib,nilotinib)or,been identified to have the T315I mutation at any time during treatment.
- Ability to understand and willingness to sign a written informed consent form. The consent form must be signed by the patient prior to any study-specific procedures.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
- Predicted life expectancy of ≥3 months.
Organ function as indicated by the following laboratory indicators must be met:
- Hemoglobin ≥8.0g/dL.
- White blood cell count ≥ 3.0×10^9/L, neutrophil count≥ 1.5 x 10^9/L.
- Platelet count ≥ 75×10^9/L.
- Serum creatinine ≤ 1.5×upper limit of normal (ULN) or 24 hours calculated creatinine clearance ≥ 50ml/min when serum creatinine >1.5×ULN.
- Serum albumin≥ 3.0 g/dL.
- Total bilirubin ≤ 1.5 x ULN.
- Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN of institution's normal range.
- Lipase≤1.5×ULN, Amylase≤1.5×ULN.
- Prothrombin time (PT), activated partial thromboplastin time (APTT), INR≤1.5×ULN.
- Cardiac function index: ejection fraction (EF) > 50%.
- Corrected QT interval (QTc) interval on electrocardiogram (ECG) evaluation: QTc≤450ms in males or ≤470ms in females.
- Willingness to use contraception by a method that is deemed effective by the investigator by both males and female patients of child bearing potential and their partners throughout the treatment period and for at least 120 days following the last dose of study drug.
- Willingness and ability to comply with study procedures and follow-up examination.
Exclusion Criteria:
- Received cytotoxic chemotherapy or radiotherapy within 28 days, interferon or cytarabine within 14 days, any investigational therapy within 14 days prior to the first dose of study drug, or have not recovered (> grade 1 by NCI CTCAE v 4.03) from adverse events (AEs ) (except alopecia) due to agents previously administered.
- Require concurrent treatment with drugs that may have interactions with the study drug.
- Have previously been treated with ponatinib (or drugs of similar composition).
- Absorption disorder syndrome or other diseases affecting oral drug absorption.
- Have any history of heart or vascular disease, such as hypertension (systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90mmHg), or take medications that are known to cause prolonged ECG QT interval.
- Mean pulmonary artery pressure >25 mmHg.
- Have a history of serious cardiovascular diseases during the previous treatment of chronic myeloid leukemia with TKI.
- Underwent autologous or allogeneic stem cell transplant.
- Abnormal coagulation function,or have a bleeding disorder within 3 months before first administration.
- Underwent major surgery (with the exception of minor surgical procedures, such as placement or bone marrow biopsy) with 14 days prior to first dose of study drug.
- Require concurrent treatment with immunosuppressive agents, other than corticosteroids prescribed for a short course of therapy.
- Have active nervous system (CNS) disease as evidence by cytology or pathology. In the absence of clinical CNS disease, lumbar puncture is not required.
- History of primary malignancy (cured for more than 5 years, completely resected superficial skin cancer other than melanoma, adequately treated in-situ cancer, or controlled prostate cancer will not be considered exclusionary).
- Active symptomatic infection.
- Known to be allergic to study drug ingredients or their analogues.
- Are pregnant or lactating or expecting pregnancy during the study program.
- Suffer from any condition or illness that, in the opinion of the Investigator or the sponsor, would compromise patient safety or interfere with the evaluation of the safety of the study drug.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A group
Subjects in the group A will be given HQP1351 after fasting meal on Day 1. Then after a seven-day of cleaning time, subjects in the group A will be given HQP1351 after 30 minutes of high-fat meal on Day 8.
|
Orally, single dose of 30mg on day 1 and day 8.
|
Experimental: B group
Subjects in the group B will be given HQP1351 after 30 minutes of high-fat meal on Day 1. Then after a seven-day of cleaning time, subjects in the group B will be given HQP1351 after fasting meal on Day 8.
|
Orally, single dose of 30mg on day 1 and day 8.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the curve from the time of dosing to infinity [AUC(0-inf)]
Time Frame: 1-5 days after every drug administration
|
Area under the plasma concentration-time curve from time zero extrapolated to infinity time of HQP1351.
|
1-5 days after every drug administration
|
Area under the curve from the time of dosing to the last measurable concentration [AUC(0-last)]
Time Frame: 1-5 days after every drug administration
|
Area under the plasma concentration-time curve from time zero to the last measurable time point of HQP1351.
|
1-5 days after every drug administration
|
Percentage of AUC(0-inf)_obs due to extrapolation from the last measurable time point to infinity (AUC_%Extrap)
Time Frame: 1-5 days after every drug administration
|
Percentage of area under the concentration time curve from time zero extrapolated to infinite time obtained by extrapolation of HQP1351.
|
1-5 days after every drug administration
|
Maximum observed concentration (Cmax)
Time Frame: 1-5 days after every drug administration
|
Maximum observed plasma concentration of HQP1351.
|
1-5 days after every drug administration
|
Time of maximum observed concentration (Tmax)
Time Frame: 1-5 days after every drug administration
|
Time to maximum observed plasma concentration of HQP1351.
|
1-5 days after every drug administration
|
Terminal elimination half life (T1/2)
Time Frame: 1-5 days after every drug administration
|
Terminal elimination half life (T1/2) is defined as the duration until observation of half of the maximum concentration of HQP1351.
|
1-5 days after every drug administration
|
Total body clearance for extravascular administration (CL/F)
Time Frame: 1-5 days after every drug administration
|
Apparent clearance of HQP1351 following oral dosing.
Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose of HQP1351 (apparent oral clearance) is influenced by the fraction of dose absorbed.
|
1-5 days after every drug administration
|
Volume of distribution based on the terminal phase for extravascular administration (Vz/F)
Time Frame: 1-5 days after every drug administration
|
Apparent volume of distribution of HQP1351.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Apparent volume of distribution of HQP1351 after oral dose (Vz/F) is influenced by the fraction absorbed.
|
1-5 days after every drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of toxicity
Time Frame: up to 12 days
|
Incidence of toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
|
up to 12 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 25, 2019
Primary Completion (Actual)
November 16, 2019
Study Completion (Actual)
November 16, 2019
Study Registration Dates
First Submitted
March 12, 2019
First Submitted That Met QC Criteria
March 17, 2019
First Posted (Actual)
March 20, 2019
Study Record Updates
Last Update Posted (Actual)
January 22, 2020
Last Update Submitted That Met QC Criteria
January 19, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HQP1351LC104
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myeloid Leukemia, Chronic Phase
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
ChemGenex PharmaceuticalsTerminatedMyeloid Leukemia, Chronic, Chronic-Phase | Myeloid Leukemia, Chronic | Myeloid Leukemia, Chronic, Accelerated-Phase | Blast PhaseUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myelogenous Leukemia - Chronic PhaseChina
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
Korean Society of HematologyNot yet recruitingChronic Myeloid Leukemia, Chronic Phase
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.RecruitingCML, Chronic Phase | CML, Accelerated PhaseChina
Clinical Trials on HQP1351
-
Ascentage Pharma Group Inc.HealthQuest Pharma Inc.CompletedChronic Myeloid Leukemia (CML)China
-
xunaNanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital... and other collaboratorsWithdrawnProphylactic HQP1351 Therapy | Third Generation TKIChina
-
Ascentage Pharma Group Inc.HealthQuest Pharma Inc.RecruitingSolid Tumor, Adult | Gastrointestinal Stromal Tumor (GIST)China
-
Ascentage Pharma Group Inc.Active, not recruitingChronic Myeloid Leukemia, Chronic PhaseChina
-
Ascentage Pharma Group Inc.Active, not recruitingChronic Myeloid Leukemia - Accelerated PhaseChina
-
Shenzhen Second People's HospitalRecruitingChronic Myeloid Leukemia, Chronic Phase | Olverembatinib | Tyrosine Kinase InhibitorsChina
-
Ascentage Pharma Group Inc.RecruitingMyeloid Leukemia | Chronic Myeloid Leukemia | Philadelphia Positive Acute Lymphoblastic Leukemia | Leukemia, Myeloid, Chronic | B Cell Precursor Type Acute LeukemiaUnited States
-
Nanfang Hospital of Southern Medical UniversityRecruitingChronic Myeloid Leukemia in Myeloid Blast Crisis | Chronic Myeloid Leukaemia Transformation | Chronic Myeloid Leukemia - Accelerated Phase | Chronic Myeloid Leukemia in Lymphoid Blast CrisisChina
-
Foundation for Liver ResearchCompleted
-
Foundation for Liver ResearchKyowa Kirin Co., Ltd.CompletedChronic Hepatitis CNetherlands